期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

GLP-1及其受体激动剂Exendin-4临床适应症的扩展 被引量：1

Expanding the Clinical Indications of GLP-1 and Its Receptor Agonist Exendin-4
下载PDF
导出
摘要 GLP-1及其受体激动剂Exendin-4是治疗糖尿病的一种理想药物,是近年来新的研究热点之一。近年发现,该类药物可从多个生理角度发挥功能,揭示其临床适应症可能有进一步的扩展空间。对GLP-1及Exendin-4的各种已知和潜在的临床适应症进行了概述,这些适应症除了各型糖尿病外,还包括肥胖症、神经系统和心脏的疾病以及其他各种潜在适应症。 GLP-1 and its receptor agonist Exendin-4 are more ideal drugs for treating diabetic. They exert its function from different physiological angles,that revealed the possibility of new clinical indications. A comprehensive review was made about the clinical indication of GLP-1 and Exendin-4,including some type diabetic,obesity,nervous system diseases,protection of heart and potential indications.
作者 王晓婧 赵丽艳 孟婧垚 李品颖 邹卫
机构地区 石药集团中奇制药技术有限公司
出处 《生物技术通报》 CAS CSCD 北大核心 2010年第4期43-46,74,共5页 Biotechnology Bulletin
关键词 GLP-1 EXENDIN-4 临床适应症 糖尿病 潜在适应症 GLP-1Exendin-4Clinical indicationDiabeticPotential indications
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献29

  • 1Moore B,Edie ES,Abram JH.On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane.Biochem J,1906,1:28-38.
  • 2曹洁,张韬威,胡昭宇.2型糖尿病患者血清GLP-1与C肽、血糖的相关性研究[J].贵州医药,2008,32(11):975-977. 被引量：11
  • 3Green BD,Flatt PR,Bailey CJ.Dipeptidyl peptidase Ⅳ(DPP Ⅳ) inhibitors:A newly emerging drug class for the treatment of type 2 diabetes.Diab Vasc Dis Res,2006,3(3):159-165.
  • 4Hansen L,Deacon CF,Orskov C,et al.Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of porcine intestine.Endocrinology,1999,140(11):5356.
  • 5Tibaduiza EC,Chen C,Beinborn M.A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain.J Biol Chem,2001,276(41):37787-37793.
  • 6Doyle ME,Egan JM.Mechanisms of action of glucagon-like peptide 1 in the pancreas.Pharmacol Ther,2007,113(3):546-593.
  • 7Creutzfeldt WO,Kleine N,Willms B,et al.Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like pep tide 1 (7-36) amide in type I diabetic patients.Diabetes Care,1996,19(6):580-586.
  • 8Fung M,Thompson DM,Shapiro RJ,et al.Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islettransplantation in type 1 diabetes.Diab Res Clin Pract,2006,74(2):189-193.
  • 9Wideman RD,Yu IL,Webber TD,et al.Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).PNAS,2006,103(36):13468-13473.
  • 10Amylin Pharmaceuticals Inc.Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus[P].US6506724 B1.2003-01-14.

二级参考文献81

共引文献20

同被引文献27

  • 1中华医学会糖尿病学分会.中国2型糖尿病防治指南[M].北京:北京大学医学出版社,2011:15-16.
  • 2Edavalath M, Stephens JW. Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives [ J ]. Patient Prefer Adherence,2010,4 : 61-68.
  • 3Chia CW, Egan JM. Role and development of GLP-1 receptor in the management of diabetes [ J ]. Diabetes Metab Syndr Obes, 2009, 2:37.
  • 4Gallwitz B. The evolving place of incertin-based therapies in type 2 diabetes [J]. Pediatr Nephrol, 2010,25 ( 7 ) : 1207-1217.
  • 5Gallwitz B. Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists [ J ]. Rev Diabet Stud, 2009,6 ( 4 ) : 247-259.
  • 6Bose AK, Mocanu MM, Carr RD,et al. Glucagon-like peptide 1 can directly protect the heart against ischemiafreperfusion injury [ J ]. Diabetes, 2005,54 ( 1 ) : 146 -151.
  • 7Mundil D, Camem-Vendrigl A, Husain M. GLP-1 receptor ago- nists: A clinical perspective on cardiovascular effects [ J ]. Dial) Vasc Dis Res,2012,9(2) :95-108.
  • 8Chinda K, Palee S, Sorinkaew S, et al. Cardiopmtecfive effect of dipeptidyl peptid-4 inhibitor during ischemia-repeffusion injury [J]. Int J Cardid,2013,167(2) :451457.
  • 9Yin M,Sillje HH,Meissner M, et al. Early and late effects of the DPP4 inhibitor vildagliptin in a rat model of post-myocardial infar- action heart failure[ J]. Cardiovase Diabetol,2011,10 ( 1 ) :85.
  • 10Read P, Khan F,l-leek P, et al. DPP-4 inhibition by sitagliptin improves the my0eardial response to dobutamine stress and miti- gates stunning in a pilot study of patients with coronary artery dis- ease[ J ]. Circ Cardiovasc Imag,2010,3 ( 2 ) : 195-201.

引证文献1

二级引证文献1

生物技术通报
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部